Oraya Therapeutics

by Michael Lachman Four years following Food & Drug Administration (FDA) approval of the anti-VEGF (vascular endothelial growth factor) drug ranibizumab ( Lucentis ) from Genentech Inc. / Roche

AAO Highlights: Back (of the Eye) to the Future by Michael Lachman and Mary Thompson The 2009 meeting of the American Academy of Ophthalmology (AAO), held in San Francisco in October, showcased the la

A look at financing, M&A, and alliance activity July–September 2009 In this issue, we present another installment of our quarterly review of medical device and in vitro diagnostics/research dealmaki

Biopharmaceutical, medical device, and in vitro diagnostics start-up dealmaking from July through September 2009. Data from Elsevier's Strategic Transactions. Deanna F. Deinzer Financings In the third